S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

NYSE:JNJJohnson & Johnson Stock Price, Forecast & News

$146.97
-1.06 (-0.72 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$146.37
Now: $146.97
$149.23
50-Day Range
$137.81
MA: $145.04
$150.01
52-Week Range
$109.16
Now: $146.97
$157.00
Volume6.38 million shs
Average Volume8.89 million shs
Market Capitalization$386.95 billion
P/E Ratio21.49
Dividend Yield2.73%
Beta0.69
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; sterilization and disinfection products to reduce surgical infection; diabetes care products; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. It has research and collaboration alliance with Morphic Therapeutic. The company was incorporated in 1887 and is based in New Brunswick, New Jersey.
Read More
Johnson & Johnson logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 4.2Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.44 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP47816010
Phone732-524-0400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$82.06 billion
Cash Flow$11.39 per share
Book Value$22.60 per share

Profitability

Net Income$15.12 billion

Miscellaneous

Employees132,200
Outstanding Shares2,632,823,000
Market Cap$386.95 billion
Next Earnings Date10/20/2020 (Estimated)
OptionableOptionable
$146.97
-1.06 (-0.72 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

How has Johnson & Johnson's stock been impacted by COVID-19 (Coronavirus)?

Johnson & Johnson's stock was trading at $131.80 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, JNJ stock has increased by 11.5% and is now trading at $146.97.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Johnson & Johnson?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Johnson & Johnson
.

When is Johnson & Johnson's next earnings date?

Johnson & Johnson is scheduled to release its next quarterly earnings announcement on Tuesday, October 20th 2020.
View our earnings forecast for Johnson & Johnson
.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) posted its quarterly earnings data on Thursday, July, 16th. The company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.17. The company earned $18.34 billion during the quarter, compared to analysts' expectations of $17.73 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The firm's revenue was down 10.8% compared to the same quarter last year. During the same quarter last year, the business earned $2.58 EPS.
View Johnson & Johnson's earnings history
.

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson announced a quarterly dividend on Monday, July 20th. Investors of record on Tuesday, August 25th will be paid a dividend of $1.01 per share on Tuesday, September 8th. This represents a $4.04 dividend on an annualized basis and a yield of 2.75%. The ex-dividend date of this dividend is Monday, August 24th.
View Johnson & Johnson's dividend history
.

How will Johnson & Johnson's stock buyback program work?

Johnson & Johnson announced that its Board of Directors has initiated a share buyback plan on Monday, December 17th 2018, which permits the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 1.5% of its shares through open market purchases. Shares buyback plans are often an indication that the company's board believes its shares are undervalued.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson issued an update on its FY20 earnings guidance on Thursday, July, 16th. The company provided earnings per share (EPS) guidance of $7.75-7.95 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.75. The company issued revenue guidance of $81.0-82.5 billion, compared to the consensus revenue estimate of $79.70 billion.

What price target have analysts set for JNJ?

16 brokers have issued 1-year price objectives for Johnson & Johnson's shares. Their forecasts range from $155.00 to $182.00. On average, they anticipate Johnson & Johnson's stock price to reach $164.27 in the next year. This suggests a possible upside of 11.8% from the stock's current price.
View analysts' price targets for Johnson & Johnson
.

Has Johnson & Johnson been receiving favorable news coverage?

Media coverage about JNJ stock has been trending neutral this week, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Johnson & Johnson earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Johnson & Johnson
.

Are investors shorting Johnson & Johnson?

Johnson & Johnson saw a drop in short interest in the month of February. As of February 15th, there was short interest totaling 18,160,000 shares, a drop of 13.0% from the January 31st total of 20,870,000 shares. Based on an average daily volume of 6,690,000 shares, the days-to-cover ratio is currently 2.7 days. Approximately 0.7% of the company's stock are short sold.
View Johnson & Johnson's Short Interest
.

Who are some of Johnson & Johnson's key competitors?

What other stocks do shareholders of Johnson & Johnson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Johnson & Johnson investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Walt Disney (DIS), Cisco Systems (CSCO), JPMorgan Chase & Co. (JPM), Intel (INTC), Procter & Gamble (PG), NVIDIA (NVDA) and AbbVie (ABBV).

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the following people:
  • Mr. Alex Gorsky, Chairman & CEO (Age 59)
  • Mr. Joseph J. Wolk CPA, Exec. VP & CFO (Age 52)
  • Dr. Paulus A. Stoffels, Chief Scientific Officer (Age 57)
  • Mr. Michael H. Ullmann, Exec. VP & Gen. Counsel (Age 60)
  • Mr. Joaquin Duato, Vice Chairman of Exec. Committee (Age 56)

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

Who are Johnson & Johnson's major shareholders?

Johnson & Johnson's stock is owned by a variety of retail and institutional investors. Top institutional investors include Swiss National Bank (0.43%), Sumitomo Mitsui Trust Holdings Inc. (0.43%), PNC Financial Services Group Inc. (0.30%), New York State Common Retirement Fund (0.25%), Macquarie Group Ltd. (0.20%) and Principal Financial Group Inc. (0.17%). Company insiders that own Johnson & Johnson stock include Alex Gorsky, Ashley Mcevoy, Charles Prince, Hubert Joly, Joaquin Duato, Kathryn E Wengel, Marillyn A Hewson, Michael E Sneed, Peter Fasolo, Ronald A Kapusta and William D Perez.
View institutional ownership trends for Johnson & Johnson
.

Which major investors are selling Johnson & Johnson stock?

JNJ stock was sold by a variety of institutional investors in the last quarter, including Toronto Dominion Bank, Bank of Nova Scotia, Fisher Asset Management LLC, Yacktman Asset Management LP, Russell Investments Group Ltd., Cooke & Bieler LP, Macquarie Group Ltd., and Healthcare of Ontario Pension Plan Trust Fund. Company insiders that have sold Johnson & Johnson company stock in the last year include Ashley Mcevoy, Kathryn E Wengel, and Michael E Sneed.
View insider buying and selling activity for Johnson & Johnson
.

Which major investors are buying Johnson & Johnson stock?

JNJ stock was acquired by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, PNC Financial Services Group Inc., Oregon Public Employees Retirement Fund, MERIAN GLOBAL INVESTORS UK Ltd, Atalanta Sosnoff Capital LLC, Pacer Advisors Inc., Alberta Investment Management Corp, and Cairn Investment Group Inc.. Company insiders that have bought Johnson & Johnson stock in the last two years include Charles Prince, Hubert Joly, Marillyn A Hewson, and William D Perez.
View insider buying and selling activity for Johnson & Johnson
.

How do I buy shares of Johnson & Johnson?

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Johnson & Johnson's stock price today?

One share of JNJ stock can currently be purchased for approximately $146.97.

How big of a company is Johnson & Johnson?

Johnson & Johnson has a market capitalization of $386.95 billion and generates $82.06 billion in revenue each year. The company earns $15.12 billion in net income (profit) each year or $8.68 on an earnings per share basis. Johnson & Johnson employs 132,200 workers across the globe.

What is Johnson & Johnson's official website?

The official website for Johnson & Johnson is www.jnj.com.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.